|85.90||-0.2900||-0.34%||Vol 895.85K||1Y Perf -1.96%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||121.00||Analyst Rating||Moderate Buy 1.82|
|Potential %||40.86||Finscreener Ranking||★★ 44.63|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 42.14|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 57.36|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||14.42||Earnings Rating||Strong Buy|
|Market Cap||16.16B||Earnings Date||25th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||25th Oct 2023|
|Estimated EPS Next Report||0.27|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.64M|
|Avg. Monthly Volume||1.28M|
|Avg. Quarterly Volume||1.19M|
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock closed at 85.9 per share at the end of the most recent trading day (a -0.34% change compared to the prior day closing price) with a volume of 895.85K shares and market capitalization of 16.16B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3059 people. BioMarin Pharmaceutical Inc. CEO is Jean-Jacques Bienaime.
The one-year performance of BioMarin Pharmaceutical Inc. stock is -1.96%, while year-to-date (YTD) performance is -17%. BMRN stock has a five-year performance of -15.03%. Its 52-week range is between 80.53 and 117.77, which gives BMRN stock a 52-week price range ratio of 14.42%
BioMarin Pharmaceutical Inc. currently has a PE ratio of 258.80, a price-to-book (PB) ratio of 4.42, a price-to-sale (PS) ratio of 12.77, a price to cashflow ratio of 114.60, a PEG ratio of 4.95, a ROA of 1.48%, a ROC of 1.59% and a ROE of 2.05%. The company’s profit margin is 9.10%, its EBITDA margin is 10.90%, and its revenue ttm is $1.56 Billion , which makes it $8.39 revenue per share.
Of the last four earnings reports from BioMarin Pharmaceutical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.27 for the next earnings report. BioMarin Pharmaceutical Inc.’s next earnings report date is 25th Oct 2023.
The consensus rating of Wall Street analysts for BioMarin Pharmaceutical Inc. is Moderate Buy (1.82), with a target price of $121, which is +40.86% compared to the current price. The earnings rating for BioMarin Pharmaceutical Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioMarin Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioMarin Pharmaceutical Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.07, ATR14 : 1.92, CCI20 : -112.80, Chaikin Money Flow : 0.01, MACD : -0.81, Money Flow Index : 41.36, ROC : -2.23, RSI : 39.70, STOCH (14,3) : 6.40, STOCH RSI : 0.00, UO : 46.73, Williams %R : -93.60), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioMarin Pharmaceutical Inc. in the last 12-months were: Bienaime Jean (Option Excercise at a value of $14 952 105), Bienaime Jean (Sold 184 000 shares of value $18 024 984 ), Brian Mueller (Sold 0 shares of value $-952 914 ), Brian Mueller (Sold 17 380 shares of value $1 817 696 ), G. Eric Davis (Option Excercise at a value of $199 904), George Eric Davis (Option Excercise at a value of $99 952), Heron Elaine (Option Excercise at a value of $576 385), Jean-Jacques Bienaime (Sold 0 shares of value $-5 696 040 ), Jean-Jacques Bienaime (Sold 92 000 shares of value $9 361 492 ), Jeffrey R. Ajer (Sold 3 000 shares of value $258 360 ), Jeffrey Robert Ajer (Option Excercise at a value of $3 322 690), Jeffrey Robert Ajer (Sold 49 000 shares of value $5 668 937 ), Mark J. Alles (Buy at a value of $314 469), Richard A. Meier (Option Excercise at a value of $576 385), V. Bryan Lawlis (Sold 0 shares of value $-576 385 ), V. Bryan Lawlis (Sold 8 500 shares of value $825 265 )
Wed, 05 Jul 2023 05:05 GMT Positive Report for BioMarin Pharmaceutical (BMRN) from BMO Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.